Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor ...

Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate. However, primary and secondary resistance have ...

Erlotinib is a quinazoline derivative that selectively and reversibly inhibits the tyrosine kinase activity of the EGFR. Here, we review the mechanism(s) of action of erlotinib, as well as the ...

Tyrosine kinase inhibitors (TKIs) are a group of drugs that interfere with the signal transduction pathways of protein kinases, compete with ATP for the ATP binding site of PTK, and reduce tyrosine ...

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report).

Nuvalent's promising lead candidates and strong investor interest has put the stock under the spotlight. Read more about the ...